Text
The acquisition is the culmination of a strategic partnership initiated in 2020 to accelerate the development of yeasts for sustainable production of fermented ingredients.
Digbi Health is enrolled in Novo Nordisk's Global Prevention Accelerator Program for the prevention of obesity and related cardiometabolic conditions.
The findings of a new research illuminate the link between IBS and gut bacteria, and suggest that histamine is a good target for therapies against the condition.
The findings of a new research suggest that during the early maturation, the microbiota would be more likely to be influenced by other microbiotas on a not-too-distant level of maturity.
AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries.
Metabolon and the Oxford Parkinson's Disease Centre will identify new metabolomic biomarkers to advance Parkinson's research and detect new therapeutic targets
The results of a new research done in mice suggest that gut bacteria can regulate host physiology by metabolizing vitamin A.
Probiotic supplements with ethanol-metabolizing activity may help reduce the disease burden of excessive alcohol consumption.
New research in mice suggests that two MACs, L-arabinose and sucrose, have specific effects on gut microbes that may prevent diet-induced obesity.
The findings of a new research show that gut bacteria can become harmful over time by gaining the ability to escape the intestine and persist in other organs where they…
